This conference uniquely brings together members of the financial community and business leaders from established and emerging companies in the dermatology space to help foster investment and partnerships in the next generation of dermatology companies and products.
Mr. Martin Babler has served as our Chief Executive Officer since April 2011. From December 2007 to April 2011, Mr. Babler served as President and Chief Executive Officer of Talima Therapeutics, Inc., a pharmaceutical company. From 1998 to 2007, Mr. Babler held several positions at Genentech, Inc., a biopharmaceutical company, most notably as Vice President, Immunology Sales and Marketing. While at Genentech he also helped to build and lead the Commercial Development organization and led the Cardiovascular Marketing organization. From 1991 to 1996, Mr. Babler was employed at Eli Lilly and Company, a pharmaceutical company, in a position focused on sales, sales management, global marketing and business development. Mr. Babler presently serves on the Emerging Companies Section and Health Section Governing Boards of the Biotechnology Innovation Organization, or BIO, and was a board member of ZS Pharma, Inc., a biotechnology company, until its sale to AstraZeneca Inc., a pharmaceutical company.
Mr. Babler holds a Swiss Federal Diploma in pharmacy from the Federal Institute of Technology in Zurich and completed the Executive Development Program at the Kellogg Graduate School of Management at Northwestern University.
Greg Licholai, MD is on faculty at Yale University and is the Chief Medical Information Officer at PRA Health Sciences, a global drug development service firm. Previously, he was President and Chief Medical Officer at Castle Creek Pharmaceuticals and responsible for all research and development activities. Earlier he was founder and President of Elipdera, focused on rare genetic and metabolic diseases, and at Amicus Therapeutics, focused on pharmacological chaperones for rare diseases. He was director of Ventures and Business Development at Medtronic Neurological, where he was responsible for approval of a novel implantable device to treat pediatric dystonia.
He trained at the Brigham and Women's, Children's, and Massachusetts General Hospitals, was a Howard Hughes Medical Institute Research Scholar at the National Institutes of Health, performed research in molecular genetics at Yale University and worked in molecular oncology at Rockefeller University. He received a B.S. from Boston College, Pre-Medical studies at Columbia University, an M.D. from Yale Medical School and an M.B.A from Harvard Business School. He is on the advisory boards of the National Tay Sachs and Allied Disease Foundation and the Partnership for Palliative Care, Yale Healthcare Conference and Yale Center for Biomedical Innovation and Technology and a lecturer at the Harvard Innovation Lab as well as Yale School of Management.
Raymond A. Miller is a partner and member of the Leadership Team of the Health Sciences Department of Pepper Hamilton LLP, resident in the Pittsburgh office. A registered patent attorney, Mr. Miller focuses his practice on identifying, protecting, securing and maximizing the value of clients' intellectual property. Mr. Miller is a former member of the firm's Executive Committee and was previously co-chair of the firm's Intellectual Property Department.
Mr. Miller's clients include universities, research institutes and businesses ranging from idea stage through Fortune 500 companies, as well as other organizations and individuals involved in basic research and technology transfer. He has represented Ivy League universities, research organizations, pharmaceutical companies, biotechnology companies, consumer products companies, manufacturing companies, computer software developers and R&D contractors. His practice includes both prosecution and transactional IP, including acquiring and licensing patents, trademarks, copyrights and trade secrets, as well as litigation.
Mr. Miller's practice includes an array of chemical, medical, pharmaceutical, mechanical, environmental and business method fields. While he is particularly adept at handling technologies in the life sciences, he also is proficient in areas of material sciences, metallurgy, thin-film technology, specialty chemicals, polymer chemistry, nanotechnology and cosmetics.
During his 17-year tenure, Allergan was transformed from a small eye care business with about $1 billion in sales to a global specialty pharmaceutical and medical device company, with sales over $7 billion in 2014 with most of the increase stemming from organic growth. Allergan’s market capitalization increased from $2.3 billion in 1998 to $72 billion when Allergan was acquired by Actavis in 2015. Subsequently, the company was renamed Allergan PLC. Dr. Pyott was recognized by Harvard Business Review as one of “The 100 Best Performing CEOs in the World” in 2014 (ranked #4). He has lived in 10 countries and worked in 7 countries ranging from the U.S. to Europe and Asia.
In 2006, Dr. Pyott was bestowed with the honor of Commander of the Most Excellent Order of the British Empire (CBE) by Her Majesty the Queen. Dr. Pyott holds a Diploma in International and European Law from the Europa Institute at the University of Amsterdam, a Master of Arts degree and an Honorary Degree in Medicine from the University of Edinburgh and a Master of Business Administration degree from the London Business School. He also has an Honorary Degree in Pharmaceutical Sciences from Chapman University in California. Dr. Pyott is Lead Director and a member of the Board of Directors of Avery Dennison Corporation, a member of the Board of Alnylam Pharmaceuticals Inc., BioMarin Pharmaceutical Inc., a member of the Supervisory Board of Royal Philips in the Netherlands and Chairman of privately held Bioniz Therapeutics and a Director of privately held Rani Therapeutics. He is a Special Advisor to Sienna Biopharmaceuticals. He is Deputy Chairman of the Board of Governors of London Business School, a Trustee of the California Institute of Technology, President of the International Council of Ophthalmology Foundation and is also involved on the Boards of many of the other US and international eyecare charities.
Professor Riedemann is co-founder of InflaRx and has served as Chief Executive Officer since inception of the company in 2007. Under his leadership, InflaRx was funded by international investors in 4 financing series and the company successfully conducted its initial public offering at the US Nasdaq stock exchange in November 2017. Throughout the company history, Prof. Riedemann was and continues to be critically involved in the scientific developments of InflaRx leading anti-human complement C5a antibody technology. He received his medical training at the Albert-Ludwig University in Freiburg, Germany and Stanford University in the United States and graduated from Albert-Ludwig University in 1998. He spent several years in basic science at the University of Michigan in the field of complement immunology and inflammation before completing his board certification as General Surgeon at the Hannover Medical School in 2007 where he still holds an adjunct Professorship for Experimental Surgery. He is specialized as Intensive Care Physician and was the Vice Director of Intensive Care Medicine at the Friedrich Schiller University in Jena, Germany from 2008 to 2015. He has served as member of the Scientific Advisory Board and the Board of Directors of two large scientific governmental funded research programs in Germany from 2012-2015. His research has been awarded with several national and international awards and he published over 50 original research articles in high ranked scientific journals. He is inventor on numerous internationally granted patents and patent applications in the complement space.
Michael Sierra, Ph.D. is currently Vice President of LEO Science & Tech Hub Cambridge (USA). Prior to this position, he held the positions of Director of Medicinal Chemistry, Director of Chemical Research, Director of External Discovery and Executive Director of Translational Research at LEO Pharma (Denmark). Before that, Michael worked 10 years at GlaxoSmithkline's Centre de Recherche, Les Ulis (France) and the biotech, CareX, Strasbourg (France) as Head of Chemistry. He received his BS in chemistry from Ohio Northern University (USA), his Ph.D. in chemistry at Wayne State University (USA) and held a 2 year post doctoral position at Ecole Polytechnique, Palaiseau (France). He has 24 years of drug discovery experience in the therapeutic areas of cardiovascular and metabolic diseases as well as inflammation and dermatology with the identification of 18 clinical candidates.
George D. Yancopoulos, MD, PhD, became the Scientific Founder and Chief Scientific Officer of Regeneron in 1989, alongside Founder and Chief Executive Office, Leonard Schleifer, MD, PhD. Dr. Yancopoulos also currently serves as President of Regeneron.
After graduating as valedictorian at both Bronx High School of Science and Columbia University, Dr. Yancopoulos received his MD and PhD in Biochemistry and Molecular Biophysics from Columbia University. Later at Columbia, he served with legendary geneticist Dr. Fred Alt as his first post-doctorate student, working in molecular immunology. Dr. Yancopoulos was pursuing a career in academia until he met Dr. Schleifer in the late 1980s and saw the potential to make a major impact on medicine through biotechnology.
Regeneron is now a leading biopharma company with more than 6,500 employees and facilities in the United States, Ireland and the United Kingdom. With a robust research and development engine and an unwavering commitment to its science-driven approach, Regeneron has produced six FDA-approved drugs, including DUPIXENT® (dupilumab) for moderate-to-severe atopic dermatitis. Dr. Yancopoulos and his team have discovered important new medicines for patients with serious diseases, including cancer, vision-threatening eye diseases and rheumatoid arthritis, while also building a robust homegrown pipeline of investigational treatments.
Dr. Yancopoulos is a principal inventor of Regeneron's foundational technologies for target discovery and drug development, such as its proprietary VelociGene® and VelocImmune® platforms. Regeneron is committed to continual innovations in the drug discovery and development processthrough the Regeneron Genetics Center, a world-leading human genetics effort that has already sequenced exomes from over 300,000 people.
Dr. Yancopoulos is passionate about bringing his success in the sciences full circle, and is deeply committed to inspiring top talent to pursue scientific careers through STEM (Science, Technology, Engineering and Math) education programs. He plays an active role in Regeneron's STEM commitments, including the Regeneron Science Talent Search (STS), the nation’s oldest and most prestigious high school science competition, formerly sponsored by Westinghouse and Intel.
Frederick C. Beddingfield III is founder, president, chief executive and member of the board of directors of Sienna Biopharmaceuticals Inc. He started Sienna in 2016 and took the company public in 2017. Prior to Sienna, Frederick served as Chief Medical Officer of Kythera Biopharmaceuticals from March 2013 until it was acquired by Allergan in 2015. Frederick worked at Allergan for 10 years (2003-2013) where he led the development of global leading brands in medical dermatology and aesthetics including Botox, Juvederm, Voluma, Kybella, Latisse, Aczone, and Tazorac. He has led multiple successful FDA advisor committees.
Since completing his training, Frederick has always maintained a clinical and teaching practice at UCLA where he is an Associate Clinical Professor. He is a board-certified dermatologist and emergency medicine physician and a fellowship trained dermatologic surgeon. Frederick completed his medical degree at UNC Chapel Hill, his residency and fellowship training at UCLA, and his PhD in Policy Analysis Research at RAND. He serves on the board of directors of Cytrellis Biosystems, Inc. and on the medical advisory board of the Children’s Skin Disease Foundation and Camp Wonder.
Albert Cha, MD, PhD. is a Managing Partner who invests in private and public biopharmaceutical and medical device companies. He currently serves on the boards of Ascendis Pharma A/S (NASDAQ: ASND), BioHaven Pharmaceuticals (NYSE: BHVN), KalVista Pharmaceuticals (NASDAQ: KALV), Menlo Therapeutics (NASDAQ: MNLO).
He was an investor in Aclaris Therapeutics (NASDAQ: ACRS), AirXpanders (ASX: AXP), ProNAi Therapeutics (NASDAQ: DNAI), Ceptaris Therapeutics (acquired by Actelion), Neomend (acquired by Bard), Vicept Therapeutics (acquired by Allergan), Bioform Medical (BFRM, acquired by Merz), Biodel (BIOD), and Aspreva Pharmaceuticals (NASDAQ: ASPV, acquired by Galenica). Albert was also involved in founding NextWave Pharmaceuticals (acquired by Pfizer) and Prestwick Pharmaceuticals (acquired by Biovail). Other investments include YM Biosciences (YMI), Dynavax Technologies (DVAX), Avanir Pharmaceuticals (AVNR), Acura Pharmaceuticals (ACUR), and AMAG Pharmaceuticals (AMAG). Albert is also a co-founder and board member of the annual Dermatology Summit and Dermatology Innovation Forum. Prior to joining Vivo, Albert worked at Oracle Corporation in pharmaceutical consulting and at the Palo Alto VA Hospital as a biomedical engineer.
John Doux, MD obtained a B.S. with distinction and an MD from Stanford University, where he was a Howard Hughes Medical Institute Fellow performing research in the laboratory of Dr. David Woodley. After an internship at Brigham and Women's Hospital in Boston, he returned to Stanford to complete his residency training in dermatology. He also completed an MBA at the Wharton School of Business where he was a Palmer Scholar. He is board certified in dermatology and maintains an active clinical practice. Since 2004 he has also served as an analyst at Palo Alto Investors, an investment fund specializing in healthcare with $2B+ in assets under management.
William Ju, MD, FAAD is a board-certified dermatologist and has over 20 years of biopharmaceutical experience in a wide variety of therapeutic areas, including dermatology. He is president and a co-founding trustee of Advancing Innovation in Dermatology, Inc. Dr. Ju has been president and chief executive officer of Follica, Inc. and chief operating officer at PTC Therapeutics, Inc. (PTCT). In addition, he has held executive positions at Pharmacia Corporation/Pfizer, Inc. Merck & Co., Inc., and Hoffmann La Roche, Inc. in a broad range of product development and leadership functions. Dr. Ju served as project leader for SUTENT®, introduced CANCIDAS® into humans, and was part of the product development teams for CRIXIVAN® and TRANSLARNA™.
Dr. Ju began his pharmaceutical career at Hoffmann-La Roche where he was a clinical leader for the development of dermatology compounds. Before entering industry, Dr. Ju was a senior staff fellow in basic research in the Laboratory of Cellular Oncology under Douglas Lowy, M.D. and was affiliated with the Dermatology Branch at the National Cancer Institute, National Institutes of Health. He obtained his M.D. with Alpha Omega Alpha honors at the University of Pennsylvania School of Medicine and his A.B. with Phi Beta Kappa honors at Princeton University. Dr. Ju is a co-founder of EdWiser, Inc. (now known as Zoomi, Inc.), is currently a member of the board of directors for Brickell Biotech, Inc., and serves on the Advisory Council for the Keller Center for Innovation Engineering Education at Princeton University.
Seth Orlow, MD, PhD has over 25 years of experience in medicine, science, and finance. As a faculty member at New York University, Dr. Orlow rose to become Chair of its leading dermatology department. He serves as a Senior Advisor with Pharus Advisors, focused on strategic transactional/investment banking advisory services in the dermatology and personal care sectors. In 1995 he co-founded Anaderm, a dermatologic discovery company backed by Pfizer and OSI Pharmaceuticals. He participated in the sale of Anaderm to Pfizer in 2002. From 2001-2010, he rose from Advisor to Partner with Easton Capital Partners, a venture capital firm focused on healthcare and consumer products. At Easton, he was involved in the sourcing, diligence, funding, oversight and exit of investments in many healthcare companies such as Acorda, Conor Medsystems, Protez, Salmedix and Transave. Dr. Orlow has licensed technologies to companies ranging from Pfizer to SkinMedica. An author of over 200 medical/scientific publications, he is an internationally sought-after speaker and thought leader. A graduate of Harvard in Biochemical Sciences and with an MD-PhD in Molecular Pharmacology from Albert Einstein College of Medicine, Dr. Orlow trained in Pediatrics and Dermatology at Mt. Sinai and Yale.
Dr. Neal Walker co-founded Aclaris Therapeutics and has served as President and Chief Executive Officer and a member of the board of directors since inception July 2012. He is a board certified dermatologist and serial entrepreneur with over 19 years of experience in the life science industry. He began his pharmaceutical industry career at Johnson & Johnson, Inc.
DDr. Walker co-founded NeXeption, LLC, a biopharmaceutical assets management company, in August 2012. Prior to Aclaris, he co-founded and served as President and Chief Executive Officer and a member of the board of directors of Vicept Therapeutics, Inc., a dermatology-focused specialty pharmaceutical company, from 2009 until its acquisition by Allergan, Inc. in July 2011. Previously, Dr. Walker co-founded and led a number of life science companies, including Octagon Research Solutions, Inc., a software and services provider to biopharmaceutical companies (acquired by Accenture plc), Trigenesis Therapeutics, Inc., a specialty dermatology company, where he served as Chief Medical Officer (acquired by Dr. Reddy's Laboratories Inc.), and Cutix Inc., a commercial dermatology company. He also co-founded and serves on the Board of Directors of the Dermatology Summit, Dermatology Innovation Forum, and Advancing Innovation in Dermatology. Dr. Walker is a director of Alderya Therapeutics, Inc., a publicly held biotechnology company, as well as several private companies.
In 2016 Dr. Walker was awarded the Frank Baldino Bioscience CEO of the Year award, and also the Ernst & Young Entrepreneur of the Year Greater Philadelphia award. He is a Fellow of the American Academy of Dermatology, received his M.B.A. degree from The Wharton School, University of Pennsylvania, his Doctor of Osteopathic Medicine degree from the Philadelphia College of Osteopathic Medicine, and a B.A. degree in Biology from Lehigh University.
This year the Dermatology Summit will be utilizing a conference app for the meeting material and networking appointments, available on both Apple and Android devices for all registered attendees.
This app will replace our conference networking software from recent years. Upon logging into the app, you will be able to network with other attendees and set up meetings in our 1:1 conference networking space.
Our app will launch in mid-November, and you will receive an email at that time with download instructions.
Conference registration includes:
If you are interested in a sponsorship opportunity, please contact Rhonda Ware at firstname.lastname@example.org, for the sponsorship overview and level pricing.
Our app will launch in mid-November, and you will receive an email at that time with download instructions to network with other conference attendees and set up 1:1 meetings in our dedicated networking space.
There are several hotels within a short distance from the Palace Hotel, where the Dermatology Summit will take place. Please reference the list of hotels below for booking your own hotel room. The Dermatology Summit does not have contracted rates with these hotels.
|Palace Hotel||2 New Montgomery Street||415-512-1111|
|Grand Hyatt San Francisco||345 Stockton Street||415-398-1234|
|Sir Francis Drake||450 Powell Street||415-392-7755|
|Westin St. Francis||335 Powell Street||800-937-8461|
|JW Marriott||510 Mason Street||415-771-8600|
|Stanford Court Hotel||905 California Street||415-989-3500|
|Prescott, A Kimpton Hotel||545 Post Street||415-563-0303|
|Hilton San Francisco Union Square||333 O'Farrell Street||415-771-1400|
|Hotel Monaco||501 Geary Street||415-292-0100|
|Ritz-Carlton||600 Stockton Street||415-296-7465|
|InterContinental Mark Hopkins||999 California Street||415-392-3434|
|The Clift Hotel||495 Geary Street||415-775-4700|
|Serrano Hotel||405 Taylor Street||415-885-2500|
|Marriott Union Square||480 Sutter Street||415-398-8900|
Attire is business casual. Feel free to be comfortable in slacks, polo shirts, blazers, blouses and most importantly, comfortable shoes. We do recommend you dress in layers as temperatures in meeting rooms can vary.
After your sponsorship has been processed, you will receive an email with a unique code and instructions to register online. We encourage all complimentary and discounted registrations to be completed by December 7, 2018. If you have not yet received the email, please contact us at email@example.com.
Requests for registration fee cancellations for the conference must be received on or before November 30, 2018 by 3pm Eastern Time. At the discretion of the conference organizers, a refund via the method of original payment, minus a $125 non-refundable administrative fee, will be issued. No refunds will be made if notice is received after 3pm Eastern Time on November 30, 2018. Written notice of your cancellation should be sent to firstname.lastname@example.org with a copy to email@example.com.
No damages or refunds shall be due for a failure of performance by the occurrence of any contingency beyond the reasonable control of AID or Caravel Group. These contingencies include, without limitation, threat of or actual war, terrorism, sabotage, insurrection, riot or other act of civil disobedience, act of public enemy, failure or delay in transportation, act of government or any agency affecting the terms of this Agreement, accident, fire, explosion, flood, severe weather, natural disaster, or other act of God, interruptions or failure of the Internet or third-party network connections, or acts beyond the reasonable control of the responsible parties making the Event impossible to hold.
Advancing Innovation in Dermatology, Inc. is a registered IRS 501(c)(3) organization designated as a public charity in the United States.